Related Links
eLearning Program
View our eLearning Program to learn more about Alpha-1.
Alpha-1 as Seen
on PBS
Watch the PBS show about Alpha-1.
ARALAST NP Dosing & Administration
The recommended dosage of ARALAST NP therapy is 60 mg/kg body weight administered once weekly by intravenous infusion. Administration of ARALAST NP therapy within three hours after reconstitution is recommended to avoid the potential ill effect of any inadvertent microbial contamination occurring during reconstitution.
ARALAST NP therapy should be administered at a rate not exceeding 0.08 mL/kg body weight/minute. If adverse events occur, the rate should be reduced or the infusion interrupted until the symptoms subside. The infusion may then be resumed at a rate tolerated by the subject.
ARALAST NP therapy is available in 1-gram and 0.5-gram vials for dosing options.
ARALAST NP [Alpha1-Proteinase Inhibitor (Human)]
ARALAST NP is indicated for chronic augmentation therapy in patients having congenital deficiency of A1-PI with clinically evident emphysema. ARALAST NP is not indicated as therapy for lung disease patients in whom congenital A1-PI deficiency has not been established.
The effect of augmentation therapy with ARALAST NP on pulmonary exacerbations and on the progression of emphysema in alpha1-antitrypsin deficiency has not been demonstrated in randomized, controlled clinical trials.
Please review the Important Risk Information and the Full Prescribing Information
Please review the Important Risk Information and the Full Prescribing Information
